Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 68.

https://doi.org/10.1182/blood-2024-208539

Published: 2024

Journal Articles

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Justin M. Darrah, Indumathy Varadarajan, Amitkumar Mehta, Jennifer N. Saultz, Matthew McKinney, Monalisa Ghosh, Usama Gergis, Girish Bende, Siddha Kasar, Bradley Hupf, Sharon Chen, Leopold Sellner, Reem Karmali

Blood (2024) 144 (Supplement 1): 95.

https://doi.org/10.1182/blood-2024-194807

Published: 2024

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

Proteomics Analysis Identifies Candidate Biomarkers for Prediction of Post-CAR-T Cytopenias

Rashmi Madhukar, Christopher Flora, Mary Olesnavich, Erin Sandford, Michelle Rozwadowski, Gen Li, Marcus Johannes Geer, Gregory Yanik, Monalisa Ghosh, David Frame, Jennifer Elise Agrusa, Challice L. Bonifant, Tania Jain, Sung W. Choi, Muneesh Tewari

Blood (2024) 144 (Supplement 1): 7168.

https://doi.org/10.1182/blood-2024-211453

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Blood (2024) 144 (Supplement 1): 887.

https://doi.org/10.1182/blood-2024-200339

Published: 2024

Journal Articles

High-Frequency Temperature Monitoring Detects Clinically Actionable Fevers Otherwise Missed By Standard-of-Care Monitoring during Treatment of Hematologic Malignancies

Shihan N. Khan, Muneesh Tewari, Seungwoo Lee, Christopher Flora, Rashmi Madhukar, Kelly Mayhew, Michelle Rozwadowski, Kay Leopold, Jason B. Weinberg, Thomas Braun, Monalisa Ghosh, David Frame, Sung W. Choi

Blood (2024) 144 (Supplement 1): 7500.

https://doi.org/10.1182/blood-2024-194678

Published: 2024

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Blood (2024) 143 (1): 21–31.

https://doi.org/10.1182/blood.2023020250

Published: 2024

Includes: Supplemental data

Journal Articles

Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma

Manisha Lin, Jonathan Weiss, Tycel J. Phillips, Dahlia Sano, Shannon A. Carty, Monalisa Ghosh, Iman Ahmed, Victoria Nachar, David Hutton, Yasmin H. Karimi

Blood (2023) 142 (Supplement 1): 256.

https://doi.org/10.1182/blood-2023-182244

Published: 2023

Journal Articles

Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

Amneet K Bajwa, Qiuhong Zhao, Marcus Johannes Geer, Agrima Mian, Chenyu Lin, David Frame, James Westholder, Justin Tossey, Monalisa Ghosh, Ahmed Galal, Nausheen Ahmed, Joseph E. Maakaron, Nathan Denlinger, Marcos de Lima, Narendranath Epperla, Paolo F. Caimi, Timothy Voorhees

Blood (2023) 142 (Supplement 1): 4502.

https://doi.org/10.1182/blood-2023-179620

Published: 2023

Journal Articles

Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation: A Feasibility Study

Mary Mansour Riwes, Jonathan Louis Golob, John M. Magenau, Costas Lyssiotis, Mengrou Shan, Gregory Dick, Thomas Braun, Thomas M Schmidt, Attaphol Pawarode, Sarah Anand, Monalisa Ghosh, John Maciejewski, Darren King, Sung W. Choi, Gregory Yanik, Marcus Johannes Geer, Ethan Hillman, Muneesh Tewari, Pavan Reddy

Blood (2023) 142 (Supplement 1): 2190.

https://doi.org/10.1182/blood-2023-181260

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Blood (2023) 142 (Supplement 1): 601.

https://doi.org/10.1182/blood-2023-180936

Published: 2023

Journal Articles

Lymphodepleting Chemotherapy before CD19 Directed CAR T-Cell Therapy: Are 3 Days Necessary?

Marcus Geer, Salena Kasha, David Frame, Monalisa Ghosh

Blood (2022) 140 (Supplement 1): 3823–3824.

https://doi.org/10.1182/blood-2022-168456

Published: 2022

Journal Articles

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Blood (2022) 140 (Supplement 1): 1459–1463.

https://doi.org/10.1182/blood-2022-158024

Published: 2022

Journal Articles

Pneumocystis Jirovecii Infection in Autologous Hematopoietic Stem Cell Transplant Recipients

John E Coda, Kadee Raser, Sarah M. Anand, Monalisa Ghosh, John Maciejewski, Attaphol Pawarode, Mary Mansour Riwes, Christina Tillman, Gregory Yanik, John M. Magenau, Matthew J. Pianko

Blood (2021) 138 (Supplement 1): 4898.

https://doi.org/10.1182/blood-2021-144633

Published: 2021

Journal Articles

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2021) 138 (Supplement 1): 165.

https://doi.org/10.1182/blood-2021-145764

Published: 2021

Journal Articles

Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study

Nathan H. Fowler, Michael Dickinson, Monalisa Ghosh, Andy Chen, Charalambos Andreadis, Ranjan Tiwari, Aisha Masood, Roberto Ramos, Vamsi Bollu, Etienne Jousseaume, Catherine Thieblemont, Martin H. Dreyling, Stephen J. Schuster

Blood (2021) 138 (Supplement 1): 3533.

https://doi.org/10.1182/blood-2021-145741

Published: 2021

Journal Articles

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Blood (2021) 138 (Supplement 1): 131.

https://doi.org/10.1182/blood-2021-145025

Published: 2021

Journal Articles

Rapid single-molecule digital detection of protein biomarkers for continuous monitoring of systemic immune disorders

Blood (2021) 137 (12): 1591–1602.

https://doi.org/10.1182/blood.2019004399

Published: 2021

Includes: Supplemental data

NARROW

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Proteomics Analysis Identifies Candidate Biomarkers for Prediction of Post-CAR-T Cytopenias

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

High-Frequency Temperature Monitoring Detects Clinically Actionable Fevers Otherwise Missed By Standard-of-Care Monitoring during Treatment of Hematologic Malignancies

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma

Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation: A Feasibility Study

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Lymphodepleting Chemotherapy before CD19 Directed CAR T-Cell Therapy: Are 3 Days Necessary?

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Pneumocystis Jirovecii Infection in Autologous Hematopoietic Stem Cell Transplant Recipients

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Rapid single-molecule digital detection of protein biomarkers for continuous monitoring of systemic immune disorders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only